Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,694 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type2 Diabetes Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 1

NCT00574665
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperinsulinemic Hyperglycemic Clamp
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 21, 2026, 11:52 AM EDT
Withdrawn Phase 4 Interventional

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

NCT03580967
View directory record Official record
Conditions
Type2 Diabetes, Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Todd Doyle
Other
Eligibility
40 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

NCT05486065
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
101
States / cities
Birmingham, Alabama • Banning, California • Chula Vista, California + 83 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PilAm Go4Health Weight Loss Program to Prevent Heart Disease

NCT02290184
View directory record Official record
Conditions
Type2 Diabetes
Interventions
PilAm Go4Health Weight-loss Program, Active Control
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

NCT00308737
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2
Interventions
Technosphere® Insulin Inhalation Powder, Usual Care
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
82
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 21, 2026, 11:52 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus

NCT01069965
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID, BGP-15 200 mg QD, BGP-15 200 mg BID, BGP-15 400 mg QD
Drug
Lead sponsor
N-Gene Research Laboratories, Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Los Angeles, California • Paramount, California • Tustin, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Not applicable Interventional

Electronic Diabetes Tune-Up Group (eDTU) for African Americans

NCT06321029
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Complications
Interventions
Diabetes Tune-Up Group
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Not applicable Interventional

Study of Duodenal-Jejunal Bypass(DJB) as a Potential Cure for Type 2 Diabetes Mellitus

NCT00562029
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Duodenal-jejunal Bypass
Procedure
Lead sponsor
Sound Shore Medical Center of Westchester
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New Rochelle, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Type 2 Diabetes Self-management Intervention for Low-income Women

NCT01284465
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Education and patient liaison combination, Control group
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
21 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 21, 2026, 11:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Growth Hormone Resistance of Beta-cells in People With a Family History of Type 2 Diabetes

NCT06571500
View directory record Official record
Conditions
Healthy, Obesity
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus

NCT01064687
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Exenatide, Placebo, Metformin, Pioglitazone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
78
States / cities
Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 4 Interventional

Semaglutide Treatment On Coronary Progression

NCT03985384
View directory record Official record
Conditions
Type 2 Diabetes, Coronary Artery Disease
Interventions
Semaglutide 2 MG/1.5 ML Subcutaneous Solution, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
40 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 2 Interventional

Comparison of Enteral Products for Tube Fed Patients With Type 2 Diabetes

NCT00544206
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
standard enteral feeding product, Diabetes specific feeding product
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2008 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 4 Interventional Results available

Liraglutide Effects on Epicardial Fat Inflammatory Genes

NCT03260881
View directory record Official record
Conditions
Type2 Diabetes, Coronary Artery Disease
Interventions
Liraglutide Pen Injector [Victoza], matching liraglutide-placebo pre-filled pens
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

NCT03617081
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0113-2023, Placebo (NNC0113-2023)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
80
States / cities
Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 21, 2026, 11:52 AM EDT
Terminated Not applicable Interventional Results available

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

NCT00790699
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
I-PORT, standard injections
Device · Other
Lead sponsor
Texas Diabetes & Endocrinology, P.A.
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Continuous Glucose Monitoring and Behavioral Change Intervention for People With Type 2 Diabetes and Diabetes Distress

NCT05941000
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Self-Monitoring of Behavior for Physical Activity, Action Planning for Physical Activity, Self-Monitoring of Behavior for Mood, Action Planning for Mood
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
45 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of PF-05175157 In Healthy Volunteers

NCT01274663
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Not applicable Interventional Results available

Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes

NCT04617795
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Omnipod 5 Automated Insulin Delivery System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

NCT01381887
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
25 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Chula Vista, California • Miramar, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 21, 2026, 11:52 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Household Participants

NCT06590649
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions
Household-level effects
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
Honolulu, Hawaii • Kapolei, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 21, 2026, 11:52 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Mulberry Leaf on Type 2 Diabetes

NCT00795704
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mulberry Leaf Extract, Placebo
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 21, 2026, 11:52 AM EDT